Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nikolakis Georgios, Alpsoy Erkan, Arenbergerova Monika, Bechara Falk G, Benhadou Farida, Cabete Joana, Caro Raffaele Dante Caposiena, Damiani Giovanni, Delage Toriel Maia, Del Marmol Veronique, Dini Valentina, Giamarellos-Bourboulis Evangelos J, Glasenhardt Katalin, Guillem Philippe, Hafner Ariela, Hristakieva Evgeniya, Ingram John R, Jarienè Vaiva, Jemec Gregor B E, Kearney Niamh, Kirby Brian, Kirsten Natalia, Krajewski Piotr K, Kucinskiene Vesta, Liakou Aikaterini I, Manzo Margiotta Flavia, Marzano Angelo V, Martorell Antonio, Matusiak Lukasz, Mintoff Dillon, Molina Leyva Alejandro, Prignano Francesca, Raudonis Tadas, Ring Hans Christian, Romanelli Marco, Şahin Samed, Saunte Ditte M L, Thorlacius Linnea, Tzellos Thrasyvoulos, Van Der Zee Hessel H, Van Straalen Kelsey, Zouboulis Christos C
Аннотация
OBJECTIVES: This study aimed to assess current prescription patterns for systemic HS therapies among European HS specialists, evaluate unmet needs in antibiotic and biologic use and explore expert opinions on criteria for biologic upgrade as a first-line therapy.
METHODS: A structured questionnaire was distributed to 55 HS specialists, the majority of whom were members of the European Hidradenitis Suppurativa Foundation (EHSF), comprising HS experts and future opinion leaders. Responses underwent statistical analysis to assess trends in antibiotic versus biologic prescription, treatment efficacy and potential improvements in therapeutic decision-making.
RESULTS: A total of 43 participants (76.6% of invited experts, 80% of invited opinion leaders) responded. While 95% adhered to licensing regulations mandating 10-12 weeks of antibiotics before biologics, 81% acknowledged prescribing antibiotics despite anticipating inadequate responses. More than half reported patient-reported flares during antibiotic treatment. The majority (77%) supported earlier biologic initiation in cases of persistent flares, and 79% favoured short-term biologic therapy over antibiotics for early-stage HS. Participants identified specific phenotypic attributes such as rapidly progressing disease, extensive involvement and comorbidities as factors warranting earlier biologic intervention.
CONCLUSIONS: Current treatment practice may delay optimal intervention, potentially leading to missed therapeutic windows. A significant proportion of respondents expressed a preference for earlier biologic intervention, especially in cases of severe disease or frequent flares. The findings underscore the need for a consensus statement defining upgrade criteria for biologics as a first-line therapy, potentially improving patient outcomes and reducing healthcare burdens.